Immunome, Inc.
Financials
Valuation Metrics
Immunome, Inc.'s Market Cap is $2.71B. At end of 2025 it was $1.88B. Ranked #1814 of 3,121 in US market (top 58%), #660 of 1,463 on NASDAQ (top 45%), #109 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.71B | US#1,814/3,121 Sec#109/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-254M | US—/3,121 Sec—/266 |
| Total Assets | $565M | US#2,724/3,121 Sec#149/266 |
| Net Assets | $525M | US#2,205/3,121 Sec#104/266 |
| Employees | 206 | US#2,488/3,121 Sec#128/266 |
| Value | ||
| P/B | 5.17x | US#2,248/3,121 Sec#145/266 |
| P/S | 391.10x | US#2,974/3,121 Sec#192/266 |
| FCF Yield | -8.07% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -48.43% | US#2,670/3,121 Sec#154/266 |
| ROA | -44.98% | US#2,967/3,121 Sec#198/266 |
| Revenue Growth | -100.00% | US#2,775/3,121 Sec#187/266 |
| Financial Health | ||
| Debt Ratio | 7.68% | US#76/3,121 Sec#35/266 |
| Total Debt | $5M | US#2,915/3,121 Sec#220/266 |
| FCF | $-219M | US#2,794/3,121 Sec#213/266 |
| Cash | $218M | US#1,677/3,121 Sec#105/266 |
| Current Ratio | 15.08x | US#169/3,121 Sec#50/266 |
| Performance | ||
| 1Y Return | 143.35% | US#88/3,121 Sec#35/266 |
| 1M Return | -19.64% | US#2,702/3,121 Sec#206/266 |
| From 52W High | -20.26% | US#1,532/3,121 Sec#110/266 |
| 1Y MDD | -33.59% | US#1,663/3,121 Sec#110/266 |
| Trading | ||
| Volume | 3,738,714 shares | US#1,517/3,121 Sec#167/266 |
| Trading Value | $89M | US#1,849/3,121 Sec#145/266 |
| Per Share | ||
| EPS | $-2.25 | US—/3,121 Sec—/266 |
| BPS | $4.64 | US#2,308/3,121 Sec#134/266 |
Company Info
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.